MedTrace Logo

An Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery

NCT01256372 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2012-03-15

No results posted yet for this study

Summary

This study investigates the effect of two dose-levels of AP214 on the prevention of (acute) kidney injury after cardiac surgery.

Conditions

  • Cardiac Surgery
  • Coronary Artery Bypass
  • Aortic Aneurysm
  • Valve Surgery
  • Kidney Diseases

Interventions

DRUG

AP214

AP214

DRUG

Placebo

Placebo; intravenous infusion

Sponsors & Collaborators

  • Action Pharma A/S

    lead INDUSTRY

Principal Investigators

  • Action Pharma · Action Pharma A/S

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-06-30
Completion
2011-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01256372 on ClinicalTrials.gov